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Our group and others have revealed 
that tumor-infiltrating T lymphocytes 
(TILs) with antineoplastic activity exists 
in cancer patients, yet are often insufficient 
to inhibit tumor growth.1 The increased 
expression of immunosuppressive mol-
ecules is one major mechanism whereby 
tumors evade immune response. One of 
these molecules is programmed death cell 
death 1 (PDCD1) ligand 1 (CD274, best 
known as PD-L1), whose intratumoral 
expression levels are inversely correlated 
with survival in patient affected by several 
malignancies.2 In addition, TILs manifest 
increased expression levels of other immu-
nosuppressive molecules, such as cyto-
toxic T-lymphocyte-associated protein 4 
(CTLA4).3 However, the precise immu-
nosuppressive mechanisms activated by 
the simultaneous engagement of multiple 
of these receptors (as opposed to the acti-
vation of individual immunosuppressive 
pathways), have not yet been delineated.
We addressed this question by assess-
ing the expression of PDCD1 (best known 
as PD-1), CTLA4 and their ligands in 
murine models of colon and ovarian car-
cinoma.4 We found that the blockade of 
PD-1 in vivo activates T cells to medi-
ate antineoplastic effects, a phenomenon 
that is greatly exacerbated by the addition 
of anti-CTLA4 antibodies. Moreover, we 
observed that a significant percentage of 
tumor-infiltrating CD8+ T cells expressed 
high levels of PD-1 (PD-1hi cells), and that 
only a fraction of these cells also expressed 
CTLA4. Conversely, very few CD8+ 
T cells were found to express CTLA4 but 
not PD-1. Importantly, most among the 
tumor-associated antigen (TAA)-specific 
CD8+ T cells belonged to the double 
positive (PD-1hiCTLA4+) population. Of 
note, such double positive cells appear 
to be functionally impaired (as demon-
strated upon stimulation with a TAA-
derived peptide), whereas PD-1hi CD8+ 
T cells maintained some function ex 
vivo, including a proliferative response to 
antigenic stimulation. These observations 
indicate that tumor-infiltrating PD-1hi 
CD8+ T cells are not entirely exhausted, 
while their PD-1hiCTLA4+ counterparts 
exhibit a severely exhausted or anergic 
phenotype.5
The mechanisms through which 
blocking immunological checkpoints 
rescues immune function in tumors is 
the subject of active investigation. The 
blockade of PD-1/PD-L1 interactions 
exerts direct stimulatory effects on CD8+ 
T cells. In addition, the blockade of 
CTLA4 and PD-1 can also activate T cells 
upon the attenuation of immunoregula-
tory circuitries, such as those mediate by 
FOXP3+CD4+ regulatory T cells (Tregs), 
and there is evidence of a cooperative 
interaction between these T cell-intrinsic 
and extrinsic effects (Fig. 1). For example, 
the blockade of CTLA4 on both Tregs 
and effector T cells (Teffs) enhances anti-
tumor immunity more efficiently than 
the inhibition of the signaling pathways 
on either cell population alone. Moreover, 
mice that completely lack CTLA4 expres-
sion develop more aggressive neoplasms 
than animals in which the CTLA4 defi-
ciency is limited to Tregs.3 A recent study 
has revealed that the PD-1 pathway also 
promotes the function of Tregs,6 and the 
blockade of PD-L1 was found to enhance 
the activity of Teffs against melanoma 
by attenuating their inhibition by Tregs.7 
In our models, tumor-infiltrating Tregs 
accumulated in parallel with the accumu-
lation of dysfunctional PD-1+CTLA4+ 
T cells. In this setting, the anti-CTLA4 
antibody 9D9, an IgG2b, did not deplete 
Tregs or impair their function in vivo, 
but promoted the proliferation of Teffs. 
Importantly, the blockade of PD-1 in 
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we have recently reported that the PD-1 and CTLa4 signaling pathways are active in both effector and regulatory 
T cells, causing profound immune dysfunctions in the tumor microenvironment. In line with this notion, the dual block-
ade of PD-1- and CTLa4-conveyed signals may exert robust therapeutic effects. here, we discuss the mechanisms pos-
sibly underlying such a synergic interaction.
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vivo had a moderate effect on Treg-
mediated immunosuppression. These 
observations offer an additional explana-
tion for the positive interaction between 
PD-1 and CTLA4 blockade. Indeed, 
the net effect of Teff inhibition appears 
to depend on the functional outcome of 
multiple receptor-ligand interactions not 
only between Teffs and antigen-present-
ing and/or target cells, but also on Tregs. 
While the blockade of PD-1 or CTLA4 
restores the antitumor activity of dysfunc-
tional T cells, the simultaneous inhibition 
of PD-1 and CTLA4 also limits the activ-
ity of Tregs. It has recently been reported 
that anti-CTLA4 IgG2a antibodies 
that promote antibody-dependent cell-
mediated cytotoxicity (ADCC) robustly 
deplete tumor-infiltrating Tregs and are 
far more effective than other IgG isotypes 
that exhibit similar neutralizing activ-
ity but stimulate weak or no ADCC.8 
Combining such Treg-depleting antibod-
ies with PD-1 blockade is likely to exert 
superior antitumor effects.
In recent clinical studies, the intra-
venous administration of anti-PD-1 or 
anti-CTLA4 monoclonal antibodies to 
patients with advanced solid tumors has 
been associated with tolerable adverse 
events and promising clinical responses.9 
This validates the translational relevance 
of a large amount of preclinical investiga-
tion and generates a great degree of enthu-
siasm. However, it is important to further 
understand how we can modulate the 
PD-1 and CTLA4 signaling pathways to 
boost TAA-specific T cells while avoid-
ing systemic T-cell activation. Our study 
supports the notion of combining the dual 
blockade of PD-1 and CTLA4 signaling 
with whole tumor cell vaccines. Indeed, 
although vaccination alone was ineffective 
in mice as it had been in the clinic,10 such a 
combinatorial regimen resulted in a robust 
therapeutic interaction. In spite of the 
technical and managerial challenges posed 
by autologous whole tumor cell vaccines, 
Figure 1. Blocking PD-1- and CTLa4-dependent immunological checkpoints synergistically enhances TCr signaling in both effector and regulatory 
T cells. (A) aKT phosphorylation is blocked by both PD-1- and CTLa4-transmitted signals, yet through different mechanisms. Indeed, while PD-1 recruits 
the tyrosine phosphatase shP2, CTLa4 operates through the serine/threonine phosphatase PP2a.5 (B) antitumor immune responses are inhibited fol-
lowing the upregulation of PD-L1 by malignant cells as well as the expression of CTLa4, PD-L1 and PD-1 by regulatory T cells (Tregs). PD-L1 on Tregs can 
indeed transmit direct immunosuppressive signals upon interaction with PD-1 on CD8+ T cells. Blocking PD-1-, PD-L1-, and CTLa4-dependent regulatory 
signals boost TCr and CD80/CD86 (B7.1/B7.2) signaling, hence reversing the dysfunction that generally affects T cells in the tumor microenvironment.
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such a combination may open the door to 
effectively targeting poorly immunogenic 
and highly aggressive cancers.
Taken together, our findings show that 
the expression of PD-1 and CTLA4 by 
TILs correlate with the degree of T-cell 
dysfunction in the tumor microenviron-
ment, and that PD-1hiCTLA4+ T cells 
comprise many TAA-specific T cells, 
strengthening the rationale for simultane-
ously targeting these immunosuppressive 
pathways. However, multiple questions 
remain unanswered. What are the pre-
cise molecular mechanisms mediating the 
positive interaction between the simul-
taneous blockade of PD-1 and CTLA4 
signaling? How are the T cell-intrinsic 
and extrinsic effects of PD-1 and CTLA4 
linked to each other? And which other 
maneuvers are critical to condition the 
tumor microenvironment so to effi-
ciently promote tumor rejection? Future 
studies will have to address these impor-
tant issues.
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